A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Open Access
- 30 April 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (9), 2658-2667
- https://doi.org/10.1158/1078-0432.ccr-11-1900
Abstract
Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose–escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors.Keywords
Other Versions
This publication has 24 references indexed in Scilit:
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyBritish Journal of Cancer, 2012
- Angiogenesis Inhibitors: Current Strategies and Future ProspectsCA: A Cancer Journal for Clinicians, 2010
- DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I studyJournal of Angiogenesis Research, 2009
- Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumoursBritish Journal of Cancer, 2008
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical ModelCancer Research, 2007
- Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursEuropean Journal Of Cancer, 2005
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine KinasesBiochemical and Biophysical Research Communications, 1999
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971